

POPULATION HEALTH RESEARCH INSTITUTE



Founded in 1999 as a joint research institute of:
McMaster University and Hamilton Health Sciences Corporation

Evolved from Preventive Cardiology and Therapeutics Research
Program (established in 1992)

PHRI's Mission

“To conduct research that improves major health outcomes for people across the world”

PHRI's Vision

“To transform health outcomes through pioneering research, operational excellence, and collaborative partnerships”

PHRI'S Philosophy and Mandate



Large, Simple, Randomized Trials



Provide leadership in international health research




Active in the education of individual researchers



Build capacity internationally for the development of global research programs

Global Network


- 6 CONTINENTS
- 105 COUNTRIES




PHRI Staff and Researchers

Researchers	101
• 64 Full-Time Researchers	
• 37 Associate Researchers	
Programs and Study Teams	184
ICT	63
Statistics and Data Management	44
Finance	15
Contracts	13
Administration, HR, Communication, Education & Operations	12
RSSM & QA	8
Executive (ED & HOO)	2
Total	442

Management Team



Scientific Organization



Research Areas Developed

- Perioperative Medicine
- Renal
- Stroke
- Genetics

New Program Initiatives

- STRIVE – Translational Research Program
- VICTOR – Virtual Care
- Brain Health
- Obesity

PHRI's Integrated Approach

PHRI's success stems from integration of expertise in:

- Knowledge of the disease
- Clinical perspective
- Trial methodology
- Research operations
- Data analysis and regulatory submissions
- Dissemination of results
- Creating global network of expert collaborators

Our Capabilities

- Study Hypothesis, Concept and Design
- Protocol Development
- Study Direction and Oversight
- Committees (Steering, adjudication, publication)
- Site Management
- Coordination of Drug Logistics
- Data Management
- Contracts
- Finance

Our Capabilities

- ICT
 - Validated custom and commercial systems
- Quality Assurance
- Clinical Research Laboratory and BioBank (CRLB)
- Core-Lab management
- Statistical analysis, reporting and dissemination of results
- Rapid Publications and Presentations
- Scientific support with Regulatory Submissions

Key Accomplishments


- > 6,000 publications since 1993
- > 250,000 participants currently enrolled worldwide in > 75 clinical studies
- Total participants enrolled in PHRI studies: >1,000,000
- Of our top-cited publications, 35 have >1000 citations
- 11 studies supported regulatory approvals globally
- 4 PHRI researchers named as top 1% of Top Cited authors
- S. Yusuf - named as top author of RCT-related publications in High Impact Journals

SCIMAGO Rankings | Health Research in Canada


Health research ranking refers to the volume, impact and quality of the institution's research output

	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UHN	2	2	2	2	1	1	1	2	2	1	2	1
PHRI	1	1	1	1	2	2	2	1	1	2	1	2
McGill University Health Centre	6	5	5	4	4	4	5	5	7	6	8	3
Sick Kids Hospital	4	3	3	3	3	3	3	3	3	3	4	5
Mt. Sinai	8	11	9	9	6	6	4	6	9	14	10	14
The Ottawa Hospital	5	6	7	11	11	9	10	8	6	8	12	15
Sunnybrook	12	10	10	8	7	8	13	16	15	23	22	19
CAMH	15	15	13	13	13	13	19	15	18	15	19	28
University of Ottawa Heart Institute	19	18	18	23	31	34	46	38	43	24	27	36
St. Josephs	25	27	25	28	22	19	24	21	24	27	39	45
Lawson Health Research Institute	36	29	29	30	33	31	33	36	36	37	46	48


Research Productivity



Research Study Count




High Impact Publications



Publications with >1000 citations



Number of Citations - January 8, 2025



Studies led to Regulatory Approvals

Study Name	Drug	Indication
HOPE	Ramipril	Secondary Prevention
RESOLVD / CHARM	Candesartan Metoprolol CR	Heart Failure Heart Failure
OASIS-4	Clopidogrel	Unstable Angina/Non-STEMI
OASIS-5	Fondaparinux	Unstable Angina/Non-STEMI
OASIS-6	Fondaparinux	ST Elevation MI
ONTARGET / TRANSCEND	Telmisartan	Prevention of CV Disease
RE-LY	Dabigatran	Prevention of Stroke in AF
AVERROES	Apixaban	Prevention of Stroke in AF
COMPASS	Rivaroxaban	CAD / PAD
REWIND	Trulicity	Reduce the risk of MACE
ANNEXa-4	Andexanet Alfa	Anti-coagulation reversal for life-threatening or uncontrolled bleeding


 www.phri.ca @PHRIresearch @PHRIresearch